8-K ·Filed May 5, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
This filing is routine and does not warrant immediate action. Monitor for future disclosure of Chae's compensation package and any strategic shifts that may accompany the co-CEO structure.
Final — all horizons settled through T+60d
APUS ▼ -83.60% at T+60d
NEUTRAL call -83.60% · α vs SPY -86.34% · entry $30.00 → $4.92
T+1d
-35.00%
call -35.00% · α -36.39%
$19.50
settled 6mo ago
T+5d
-55.33%
call -55.33% · α -57.32%
$13.40
settled 6mo ago
T+20d
-55.00%
call -55.00% · α -59.21%
$13.50
settled 5mo ago
T+60d
-83.60%
call -83.60% · α -86.34%
$4.92
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Apimeds Pharmaceuticals US appointed Sungjoon Chae as Co-CEO effective May 4, 2026, following a stockholder nomination. Compensation terms are not yet determined. The appointment is routine and carries no immediate financial implications.
Key Facts
- Sungjoon Chae appointed Co-CEO effective May 4, 2026
- Appointment made pursuant to a stockholder nomination
- Compensation terms not yet determined; will be disclosed when finalized
- No family relationships or related party transactions with the appointee
- No departure of existing officers reported
Financial Impact
No financial impact identified from this filing
Market Snapshot
Exchange
NYSE
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-052036 |
| Document: 0001213900-26-052036-index-headers.html | 0001213900-26-052036 |
| Document: 0001213900-26-052036-index.html | 0001213900-26-052036 |
| Document: 0001213900-26-052036.txt | 0001213900-26-052036 |
9 reports for APUS
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 13, 2026 14d ago | 8-K | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 1, 2026 26d ago | 8-K | $4.10 | awaiting T+60 | — | $3.05 (−25.61%) |
Sep 22, 2026 5w ago | 8-K | $2.29 | awaiting T+60 | — | $3.05 (+33.19%) |
Aug 21, 2026 9w ago | 8-K | $4.75 | awaiting T+60 | — | $3.05 (−35.79%) |
Aug 6, 2026 11w ago | 8-K | $4.23 | awaiting T+60 | — | $3.05 (−27.90%) |
May 5, 2026 25w ago | 8-K | $30.00 $4.92 | ▼ −83.60% | ▼ −86.34% | $3.05 (−89.83%) |
May 4, 2026 25w ago | 8-K | $1.88 $5.75 | ▼ −205.85% | ▼ −203.99% | $3.05 (−62.23%) |
Apr 16, 2026 27w ago | 8-K | $1.88 $0.7324 | ▲ +61.04% | ▲ +67.19% | $3.05 (−62.23%) |
Showing 9 of 9
US Market Status
Market Closed — Opens Thu (10h 48m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers